Quick Order Cart

Cat. No. ARG43923

IMMP2L Knockout KGN Cell Line

  • Product Type:

    In Stock Cell Lines

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Ovary (ovarian follicle)

  • Disease:

    Malignant granulosa cell tumor

The IMMP2L Knockout KGN Cell Line is a CRISPR/Cas9-edited knockout cell line derived from human ovarian granulosa KGN cells, designed for disruption of the IMMP2L gene. IMMP2L encodes a catalytic subunit of the mitochondrial inner membrane peptidase complex, critical for processing nuclear-encoded mitochondrial precursors and interacting with factors such as IMMP1L and OMA1. This model enables investigation of mitochondrial protein quality control, respiratory chain assembly, and steroidogenesis in granulosa cell tumors. It supports applications in reproductive cancer biology, mitochondrial dysfunction studies, and modeling of neurodevelopmental disorders linked to IMMP2L mutations. Key assays include mitochondrial respiration measurements, Western blotting, and import assays.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    KGN

    Sex of Donor

    Female

    Age

    63 years

    Derived From Site

    In situ; Ovarian follicle

    Gene Name

    IMMP2L

    Gene Identifier

    NCBI Gene ID 83943

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The IMMP2L Knockout KGN Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human ovarian granulosa cell line KGN, designed for targeted gene disruption of IMMP2L. This loss-of-function model enables precise investigation of the mitochondrial inner membrane peptidase subunit IMMP2L in a well-characterized granulosa background, offering a robust tool for dissecting mitochondrial protein processing and quality control.

The host cell line KGN is an immortalized human granulosa line established from a granulosa cell tumor. It retains key steroidogenic capacity, making it a standard model for studying ovarian folliculogenesis, steroidogenesis, and tumorigenesis. KGN cells thus provide a physiologically relevant context for exploring mitochondrial functions in endocrine and oncological settings.

IMMP2L encodes a catalytic subunit of the mitochondrial inner membrane peptidase (IMP) complex that proteolytically processes nuclear-encoded mitochondrial precursor proteins after import. It forms complexes with IMMP1L and cooperates with the mitochondrial processing peptidase (MPP) and quality control proteases OMA1 and YME1L. Upstream, IMMP2L expression is regulated by PPARGC1A, NRF1, and TFAM under mitochondrial stress signals, while downstream it cleaves respiratory chain subunits such as UQCRFS1 and CYC1, as well as mitochondrial ribosomal components, thereby ensuring proper assembly of oxidative phosphorylation complexes.

In the context of KGN granulosa cells, IMMP2L knockout likely compromises mitochondrial protein maturation, impairing respiratory chain function and steroidogenic output. This disruption is significant for examining mitochondrial dysfunction in ovarian tumorigenesis and reproductive disorders. Furthermore, given the association of IMMP2L mutations with Tourette syndrome and autism spectrum disorder, this cell line also facilitates modeling of neurodevelopmental pathologies linked to impaired mitochondrial protein quality control.

Research applications include mitochondrial respiration assays using Seahorse analysis, flow cytometric measurement of membrane potential, Western blotting for IMMP2L and targets like UQCRFS1, RT-qPCR for mitochondrial gene expression, immunofluorescence for mitochondrial morphology, and proteinase K protection assays to evaluate import efficiency. This knockout line is invaluable for studies in reproductive cancer biology, mitochondrial quality control, and neurodevelopmental disease modeling. For further information, contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)